Jun 5 2013

george

Measuring Dabi and Riva

From Kim Kinney at IU Health (formerly Clarian): Our coag lab is being asked by our heme/onc docs to have an assay for both Rivaroxaban and Dabigatran. I thought maybe you could poll your readers to see who is doing what type of assay if any! As always, thanks for your help. Hi, Kim, it is good to hear […]

read more

Comments (2)

Anticoagulant Therapy

May 9 2013

george

ARISTOTLE Analysis: Apixaban Superior to Warfarin

A May 7, 2013 report from the ARISTOTLE trial was highlighted on The Heart.Organd showed superior efficacy for apixaban versus warfarin in stroke, systemic embolism, and all-cause death. The Heart.org also provided this nicely illustrated and definitive European Heart Rhythm Association guide to the use of the new oral anticoagulants, including edoxaban, the most recent direct anti-Xa inhibitor […]

read more

Comments (0)

Anticoagulant Therapy

May 9 2013

george

POCT ACT and Anti-Xa for ECMO

From Deanna Miller, Point of Care Testing (POCT) Coordinator at Children’s of Alabama: We have recently merged our extracorporeal membrane oxidation (ECMO) team with the cardiovascular team from the University of Alabama at Birmingham (UAB) and we are doing all pediatric cardiovascular cases at Children’s now. We would like some insight into monitoring coagulation using the activated coagulation time […]

read more

Comments (2)

Anticoagulant Therapy

May 3 2013

george

Anticoagulant Reversal Protocols

From Scott Cornelius at Johnson & Johnson, I am interested in finding out if you have any samples of what good bleeding protocols for large teaching hospitals are like. With all of the new oral agents on the market there surely are many new challenges in managing patients with ICH and other serious bleeding complications. Thanks for your […]

read more

Comments (1)

Anticoagulant Therapy

May 1 2013

george

INR Reference Range?

A message from Patti Richardson and Dr. Manjula Balasubramanian, St Christopher’s Hospital for Children, Philadelphia, PA (originally posted November, 2011): Is it necessary to have a reference range for the international normalized ratio (INR)? It is a calculated value. If so, should these be derived from the normal prothrombin time (PT) ranges? The Heme CAP checklist does not […]

read more

Comments (0)

Anticoagulant Therapy

Apr 16 2013

george

POC INRs with an APA

From Elizabeth Kreuser: Our pharmacy is using a point of care (POC) device to monitor prothrombin times with international normalized ratios (INRs).  However, they have a patient with an anti-phospholipid antibody (APA).  We did a quick study using Stago Neoplastin Cl Plus, Stago clotting factor II, and the POC device. Results were: Assay  Test 1  Test […]

read more

Comments (0)

Anticoagulant Therapy

Apr 11 2013

george

New Oral A/Cs and POC

A message from Crystal Azevedo, Eastern Maine Medical Center: Hello George, I have a question regarding the new Xa inhibitors and dabigatran and point of care (POC) systems. Is there any known interference in the prothrombin time/international normalized ratio (PT/INR) determination of POC assays when a patient is on one of these medications? We are using the […]

read more

Comments (0)

Anticoagulant Therapy

Apr 4 2013

george

Omaha Presentation Handouts

George substituted for Dave McGlasson and presented, “Monitoring the New Antithrombotics: Whatever Happened to the PT and PTT?”  on Wednesday, April 3, 10 AM; and “Antiplatelet Therapy, Do Aspirin and Plavix Work?” on Thursday, April 3, 2:30–2:30 PM at the Great Plains Regional Laboratory Expo  in Omaha Nebraska. His presentation handouts, in PDF, appear on our Audio Modules page. Thanks […]

read more

Comments (0)

Anticoagulant Therapy

Apr 2 2013

george

Does Apixaban Affect Clot-based Assays?

From Linda Stang, Alberta Health Services: As apixaban (Eliquis) is sure to start wreaking havoc in some of our special coag assays (read: tests will be ordered while patients are on this drug, but they WON’T tell us…), I did a search for publications about apixaban interference, and found nothing. Does anyone have any experience with interference […]

read more

Comments (1)

Anticoagulant Therapy

Mar 25 2013

george

New Rivaroxaban Indication in Europe

On Friday, March 22 the European Medicines Agency Committee for Medicinal Products for Human Use cleared rivaroxaban (Xarelto) for prevention of atherothrombotic events in patients with acute coronary syndrome. EMA made this decision a few weeks after the US FDA disapproved the drug for the same indication. The news release appears on TheHeart.org.

read more

Comments (0)

Anticoagulant Therapy